CB1 Capital Management predicts Cannabis could disrupt the healthcare industry in a big way. The firm's Founding Partner and Chief Investment Officer Todd Harrison explains why he thinks medical marijuana will migrate from state dispensaries, to become medicine prescribed by doctors through insurance in the next decade.
Harrison says the only way the U.S. government would get their hands on the money in this market opportunity is through the FDA. "That's where we think it goes, follow the money," says Harrison.
"This is not so much a trade about commerce, as it is a trade about healthcare," said Harrison. "We think that this is going to migrate towards medicine." One of CB1 Capital Management's holdings GW Pharmaceuticals is up 30 percent over the past three months. Harrison expects this company to publish research showing the efficacy of cannabis treatment this summer.
With a merger this big, creators, studios, and theaters all face uncertain futures. Here’s what experts are worried about and what good could come from it.
With disengagement rising and hybrid work shifting, 'Everybody Matters' author Bob Chapman explains why treating people well could define the future of work.
We sat down with Ali Furman, U.S. Consumer Markets Industry Leader at consulting firm PwC to ask what trends she garnered from the initial data this year.
Seth Schachner breaks down Zootopia 2’s record-smashing debut, holiday box office trends, early 2026 Oscar contenders, and what’s next for Netflix and WBD.
Truist's Mike Skordeles unpacks earnings trends, market correction, labor force dynamics, and what a possible December rate cut could mean for all of us.
